EMA Authorised: Eklira Genuair (aclidinium bromide) — Covis Pharma Europe B.V.

View source ↗

Summary

The European Medicines Agency authorised Eklira Genuair (aclidinium bromide) for pulmonary disease (COPD) with Covis Pharma Europe B.V. as the marketing authori…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Eklira Genuair (aclidinium bromide)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: Covis Pharma Europe B.V.. Decision date: 29/07/2025